Adam D Farmer1,2,3, Anne Grave Pedersen3,4, Birgitte Brock4,5, Poul Erik Jakobsen6, Jesper Karmisholt6, Sahar D Mohammed2, S Mark Scott2, Asbjørn Mohr Drewes3, Christina Brock7,8,9. 1. Department of Gastroenterology, University Hospitals of North Midlands, Stoke on Trent, UK. 2. Centre for Neuroscience and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 3. Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Mølleparkvej 4, DK-9000, Aalborg, Denmark. 4. Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. 5. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 6. Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. 7. Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Mølleparkvej 4, DK-9000, Aalborg, Denmark. christina.brock@rn.dk. 8. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. christina.brock@rn.dk. 9. Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. christina.brock@rn.dk.
Abstract
AIMS/HYPOTHESIS: We hypothesised that type 1 diabetic patients with established diabetic sensorimotor polyneuropathy (DSPN) would have segmental and/or pan-enteric dysmotility in comparison to healthy age-matched controls. We aimed to investigate the co-relationships between gastrointestinal function, degree of DSPN and clinical symptoms. METHODS: An observational comparison was made between 48 patients with DSPN (39 men, mean age 50 years, range 29-71 years), representing the baseline data of an ongoing clinical trial (representing a secondary analysis of baseline data collected from an ongoing double-blind randomised controlled trial investigating the neuroprotective effects of liraglutide) and 41 healthy participants (16 men, mean age 49 years, range 30-78) who underwent astandardised wireless motility capsule test to assess gastrointestinal transit. In patients, vibration thresholds, the Michigan Neuropathy Screening Instrument and Patient Assessment of Upper Gastrointestinal Symptom questionnaires were recorded. RESULTS: Compared with healthy controls, patients showed prolonged gastric emptying (299 ± 289 vs 179 ± 49 min; p = 0.01), small bowel transit (289 ± 107 vs 224 ± 63 min; p = 0.001), colonic transit (2140, interquartile range [IQR] 1149-2799 min vs 1087, IQR 882-1650 min; p = 0.0001) and whole-gut transit time (2721, IQR 1196-3541 min vs 1475 (IQR 1278-2214) min; p < 0.0001). Patients also showed an increased fall in pH across the ileocaecal junction (-1.8 ± 0.4 vs -1.3 ± 0.4 pH; p < 0.0001), which was associated with prolonged colonic transit (r = 0.3, p = 0.001). Multivariable regression, controlling for sex, disease duration and glycaemic control, demonstrated an association between whole-gut transit time and total GCSI (p = 0.02). CONCLUSIONS/ INTERPRETATION: Pan-enteric prolongation of gastrointestinal transit times and a more acidic caecal pH, which may represent heightened caecal fermentation, are present in patients with type 1 diabetes. The potential implication of delayed gastrointestinal transit on the bioavailability of nutrition and on pharmacotherapeutic and glycaemic control warrants further investigation. TRIAL REGISTRATION: EUDRA CT: 2013-004375-12.
RCT Entities:
AIMS/HYPOTHESIS: We hypothesised that type 1 diabeticpatients with established diabetic sensorimotor polyneuropathy (DSPN) would have segmental and/or pan-enteric dysmotility in comparison to healthy age-matched controls. We aimed to investigate the co-relationships between gastrointestinal function, degree of DSPN and clinical symptoms. METHODS: An observational comparison was made between 48 patients with DSPN (39 men, mean age 50 years, range 29-71 years), representing the baseline data of an ongoing clinical trial (representing a secondary analysis of baseline data collected from an ongoing double-blind randomised controlled trial investigating the neuroprotective effects of liraglutide) and 41 healthy participants (16 men, mean age 49 years, range 30-78) who underwent a standardised wireless motility capsule test to assess gastrointestinal transit. In patients, vibration thresholds, the Michigan Neuropathy Screening Instrument and Patient Assessment of Upper Gastrointestinal Symptom questionnaires were recorded. RESULTS: Compared with healthy controls, patients showed prolonged gastric emptying (299 ± 289 vs 179 ± 49 min; p = 0.01), small bowel transit (289 ± 107 vs 224 ± 63 min; p = 0.001), colonic transit (2140, interquartile range [IQR] 1149-2799 min vs 1087, IQR 882-1650 min; p = 0.0001) and whole-gut transit time (2721, IQR 1196-3541 min vs 1475 (IQR 1278-2214) min; p < 0.0001). Patients also showed an increased fall in pH across the ileocaecal junction (-1.8 ± 0.4 vs -1.3 ± 0.4 pH; p < 0.0001), which was associated with prolonged colonic transit (r = 0.3, p = 0.001). Multivariable regression, controlling for sex, disease duration and glycaemic control, demonstrated an association between whole-gut transit time and total GCSI (p = 0.02). CONCLUSIONS/ INTERPRETATION: Pan-enteric prolongation of gastrointestinal transit times and a more acidic caecal pH, which may represent heightened caecal fermentation, are present in patients with type 1 diabetes. The potential implication of delayed gastrointestinal transit on the bioavailability of nutrition and on pharmacotherapeutic and glycaemic control warrants further investigation. TRIAL REGISTRATION: EUDRA CT: 2013-004375-12.
Authors: Pankaj J Pasricha; Katherine P Yates; Linda Nguyen; John Clarke; Thomas L Abell; Gianrico Farrugia; William L Hasler; Kenneth L Koch; William J Snape; Richard W McCallum; Irene Sarosiek; James Tonascia; Laura A Miriel; Linda Lee; Frank Hamilton; Henry P Parkman Journal: Gastroenterology Date: 2015-08-21 Impact factor: 22.682
Authors: V Cesario; T A Di Rienzo; M Campanale; G D'angelo; F Barbaro; G Gigante; G Vitale; G Scavone; D Pitocco; A Gasbarrini; V Ojetti Journal: Minerva Endocrinol Date: 2014-09 Impact factor: 2.184
Authors: Madhusudan Grover; Gianrico Farrugia; Matthew S Lurken; Cheryl E Bernard; Maria Simonetta Faussone-Pellegrini; Thomas C Smyrk; Henry P Parkman; Thomas L Abell; William J Snape; William L Hasler; Aynur Ünalp-Arida; Linda Nguyen; Kenneth L Koch; Jorges Calles; Linda Lee; James Tonascia; Frank A Hamilton; Pankaj J Pasricha Journal: Gastroenterology Date: 2011-02-04 Impact factor: 22.682
Authors: Louise Ladebo; Pernille V Pedersen; Grzegorz J Pacyk; Jens Peter Kroustrup; Asbjørn M Drewes; Christina Brock; Anne E Olesen Journal: Obes Surg Date: 2021-03-12 Impact factor: 4.129
Authors: Adam D Farmer; Anne Grave Pedersen; Birgitte Brock; Poul Erik Jakobsen; Jesper Karmisholt; Sahar D Mohammed; S Mark Scott; Asbjørn Mohr Drewes; Christina Brock Journal: Diabetologia Date: 2017-09-17 Impact factor: 10.122
Authors: Anne-Marie Langmach Wegeberg; Christian Stevns Hansen; Adam D Farmer; Jesper Scott Karmisholt; Asbjorn M Drewes; Poul Erik Jakobsen; Birgitte Brock; Christina Brock Journal: United European Gastroenterol J Date: 2020-05-09 Impact factor: 4.623
Authors: Grazia Aleppo; Peter Calhoun; Nicole C Foster; David M Maahs; Viral N Shah; Kellee M Miller Journal: J Diabetes Complications Date: 2017-09-06 Impact factor: 2.852
Authors: Theresa Meldgaard; Søren Schou Olesen; Adam D Farmer; Klaus Krogh; Anne Astrid Wendel; Birgitte Brock; Asbjørn Mohr Drewes; Christina Brock Journal: J Diabetes Res Date: 2018-09-16 Impact factor: 4.011
Authors: Ditte S Kornum; Astrid J Terkelsen; Davide Bertoli; Mette W Klinge; Katrine L Høyer; Huda H A Kufaishi; Per Borghammer; Asbjørn M Drewes; Christina Brock; Klaus Krogh Journal: J Clin Med Date: 2021-03-31 Impact factor: 4.241